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Cysteinyl leukotriene synthesis was investigated in patients 
with psoriasis. A non-invasive test requiring no stimulation 
was employed by measuring the major index metabolite of 
L TC4, which appears in urine. The presence of this metabo-
lite, L TE4, was shown unequivocally by gas chromato-
graphy - mass spectrometry. Routinely LTE4 was quantitated 
by specific radio immunoassay after its isolation by reversed-
phase high-performance liquid chromatography. Further-
more, in representative samples amounts of L TE4 obtained 
by radioimmunoassay were validated by gas chromato-
graphy-mass spectrometry. We demonstrate a significant 
T he pathogenesis of psoriasis includes an enhanced pro-liferation of epidermal cells associated with an inflam-matory reaction. Arachidonic acid and its Iipoxygen-ase metabolites 12-HETE [1] and LTB4 [2-4] and to a lesser extent the cyclooxygenase metabolites PGE2 
and PGF2a [1] have been found to be elevated in psoriatic skin. In 
contrast to the largely undefined biologic activity of arachidonic 
acid or 12-HETE, LTB4 has been demonstrated to be one of the 
most potent endogenously synthesized chemotactic fa~to~s [5]. In 
addition, a role of L TB~ in the pathogenesis of psonaSIS IS also 
supported by the fact that L TB4, if topically applied, iI1:duce~ neu-
trophil infiltration and the formation of microabscesses I?e~tlcal to 
those seen in psoriasis even though it does not induce psonasls [6] . In 
contrast to neutrophils, which mainly synthesize L TB4, eosinophils 
[7], basophils [8], and mast cells [9] have been shown to synthes!ze 
nearly exclusively cysteinyl leukotrienes. They are potent prom-
flammatory mediators that affect microvascular tone and permeabil-
ity. Intradermal injection of LTC4 and LTD4 in human skin has 
been shown to elicit a wheal [10] and axon reflex-mediated flare 
reaction [11]. This response was similar to that observed with hista-
mine but it was mediated neither by histamine nor by cyclooxygen-
ase products [11]. The prolonged vasodilatory effect of intrader-
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Abbreviations: 
GC-MS: gas chromatography - mass spectrometry 
HETE: hydroxyeicosatetraenoic acid . 
HTMP: 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl 
L T: leukotrienes 
NIC!: negative ion chemical ionization 
PFB-TMS: pcncafluorobenzyl-crimethylsilyl 
RIA: radio immunoassay 
RP-HPLC: reversed-phase high-performance liquid chromatography 
(p < 0.01) more than fourfold increase of urinary LTE4 in 
psoriasis compared to healthy volunteers. Urinary LTE4 was 
log normally distributed with geometric mean values (95% 
confidence intervals) of 11 (9-14) nmol LTE4/mol creati-
nine in healthy volunteers (n = 11) and 51 (28-95) nmol 
LTE4/mol creatinine in psoriasis (n = 9). The present study 
shows that cysteinyl leukotriene synthesis is enhanced in 
patients with psoriasis and that measurement of urinary L TE4 
is a useful parameter to monitor its rate of synthesis. ] Invest 
Dermato199:8-11, 1992 
mally injected LTC4 or LTD4 was also demonstrated by laser 
Doppler technique [12] . Therefore, the tortuous and leaky capil-
laries seen in psoriasis could at least partly result from the action of 
these mediators. 
The main problem in assessing endogenous synthesis of cysteinyl 
lellkotrienes is their small concentration in tissue and their rapid 
metabolism and clearance from blood [13]. So far and in contrast to 
L 'J'B4 only a few attempts have been made to determine cysteinyl 
lellkotrienes in psoriasis. In fluid from skin chambers oflesional and 
nonlesional skin the presence ofLTC4 and LTD4 immunoreactive 
material has been demonstrated [14]. 
Pharmacokinetic data obtained from man, using radioactive la-
beled L TC4, demonstrated that L TE4 is the major urinary metabo-
lite, most of which appears within 3-5 h after application [15]. The 
rapid excretion of L TE4 into urine and the fact that cysteinylleuko-
trienes are not stored intracellularly allow monitoring changes of 
the synthesis of these powerful mediators by measuring L TE4 ex-
cretion into urine. In order to evaluate a role of cysteinyl leuko-
trienes in psoriasis we measured this metabolite, which reflects 
whole-body cysteinylleukotriene synthesis. 
MATERIALS AND METHODS 
S\lhjects Nine adult patients with chronic nummular psoriasis 
vulgaris, four men and five women attending the Department of 
Dermatology of the Hannover Medical School, Hannover, Ger-
many, agreed to participate in the study. None of the patients had 
received systemic treatment or corticosteroid ointments 2 weeks 
prior to the study. The body surface affected with plaque-type psori-
asis ranged from 15 to 40%. The urine was collected 1 dafter 
attending the hospital when local therapy consisted of 3% salicylic 
acid in white paraffin. A group of healthy volunteers, five men and 
si" women, were matched to the patients with regard to gender and 
age. All of them had a negative history of psoriasis. Patients and 
volunteers were within the normal range for body weight and sur-
face area. 
Materials Leukotriene E4 was synthesized by Dr. T. Roder and 
Peo£. H. J. Bestmann, University ofErlangen, Germany. The mono-
clonal antibody was a kind gift ofF. Kohen, Weizmann Institute, 
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Rehovot, Israel. [3HJL TE4 (1.4 TBq/mmol) was purchased from 
Du Pont de Nemours, Dreieich, Germany. N-acetyl-LTE4 was pur-
chased from Cascade, Reading, England. 4-hydroxy-2,2,6,6-tretra-
methylpiperidine-1 -oxyl (HTMP) and N,N-diisopropyleth-
ylamine were purchased from Sigma, Munich, Germany. 
Pentafluorobenzyl (PFB) bromide was obtained from Aldrich, 
Steinheim, Germany. N,O-bis (trimethylsilyl) trifluoroacetamide 
was purchased from Pierce, Rockford, IL. All other reagents used 
were of analytical grade. 
Measurement of Urinary LTE. The method used herein to 
measure LTE4 in urine has been published recently [16J . Briefly, 
urine samples were collected in bottles for 24 h at 4 ° C containing 
(258 mg) HTMP, to protect LTE4 against oxidative degradation 
[17J and (558 mg) EDT A to inhibit degradation induced by ferrous 
ion [18J. Aliquots of 20 ml were then frozen and kept at - 20 °C 
until final analysis. After the addition of[3HJLTE4 (0.27 nCi/mol, 7 
fmol/ml), cysteinylleukotrienes were concentrated by solid-phase 
extraction followed by reversed-phase high-performance liquid 
chromatography (RP-HPLC) for isolation and purification. The 
amounts of L TE4 were then quantitated by radio immunoassay 
(RIA). Recovery of each sample was determined and used for calcu-
lation of L TE4 concentration. The total recovery of [3HJL TE4 (n = 
20) from 20 ml urine was 53 ± 10% (mean ± SEM). In the present 
study, measurement of urine pH was carried out on each urine 
sample. There was no difference in pH between patients and normal 
volunteers (6.6 ± 0.34 versus 6.7 ± 0.44, respectively). Urine flow 
rates were also comparable. 
Gas Chromatographic-Mass Spectrometric Analysis Due to 
the fact that pathologic samples of urine could contain additional 
compounds that could, despite the separation by RP-HPLC, bind to 
the antibody, we used gas chromatography-mass spectrometry 
(GC-MS) to verify our measurements. The identity of urinary LTE4 
was determined by GC-MS as recently described [16J . Briefly, mass 
spectra were obtained in the negative-ion chemical ionization 
(NICI) mode on a Finnigan MAT TSQ 45 gas chromatograph-
tandem mass spectrometry system. In order to analyze L TE4 by 
GC-MS, synthetic and urinary LTE4 were catalytically desulphur-
ized and hydrogenated to form 5-hydroxyeicosanoic acid, which 
was derivatized to the pentafluorobenzylester-trimethylsilylether 
(PFB-TMS). In representative samples from healthy volunteers 
(n = 2) and from psoriasis (n = 2) urinary L TE4 was quantitated by 
GC-MS using an lBO-labeled L TE4 standard [19J. 
Statistical Analysis All data are presented as mean ± SEM. Com-
parisons of L TE4 excretion between vo lunt~ers and patients with 
psoriasis were made by usmg the Mann-Whitney U test. P < 0.05 
was considered significant. 
RESULTS 
Identification ofLTE. by GC-MS Representative NIC! mass 
spectra of the PFB-TMS derivatives of 5-hydroxyeicosanoic acid 
obtained from synthetiC L TE4 and from unnary L TE4 from a patient 
with psoriasis are shown in Fig 1. Urinary LTE4 as well as synthetic 
L TE4 showed identical spectra with the two characteristic mass 
fragments of m/z 399 (M-PFBt and m/z 309 (M-PFB-
TMSOH)-. These mass spectra could theoretically also be obtained 
from endogenously synthesized LTC4, LTD4, N-acetyl-LTE4, or 
5_hydroxyeicosanoic acid. However, separation of L TE4 by RP-
HPLC from all of these other compounds excludes this possibility. 
Quantitation of L TE. by GC-MS and by RIA In order to 
validate L TE4 values obtained by RIA, representative samples were 
analyzed by GC-MS. Amounts of urinary LTE4 from healthy volun-
teers as well as from psoriasis measured by GC-MS and RIA differed 
by less than 10% (GC-MS, 75, 68, 840,1410 pg/ml; RIA, 69, 73, 
813, 1530 pg/ml, respectively) . 
Excretion ofLTE. in Healthy Volunteers In healthy volun-
teers (n = 11) urinary LTE4 was log normally distributed with a 
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Figure 1. Fragmentation patterns (NICI) of the PFB-TMS derivative of 
5-hydroxeicosanoic acid obtained from synthetic LTE. (top) and from a 
representative sample of urinary LTE. from psoriasis (bottom). 
interval: 9-14 nmol LTE4/mol creatinine) (Fig 2). There was no 
difference in excretion of LTE4 with respect to gender. The 
amounts of L TE4 excreted within 24 h were log normally distrib-
uted as well with a geometric mean of 65 ng LTE4/24 h (95% 
confidence interval: 54 - 78 ng L TE4 /24 h). 
Day to Day Variation ofLTE. Excretion To determine the 
variability of urinary L TE4 we measured L TE4 in aliquots obtained 
from 24-h urine collected on three consecutive days from six 
healthy volunteers. The coefficient of variation was 8 ± 3% 
(mean ± SD). 
Excretion ofLTE. in Psoriasis Patients with psoriasis excreted 
significantly (p ,,:;; 0.01) higher amounts of L TE4 either expressed as 
excretion within 24 h or expressed as nmol LTE4/mol creatinine 
with respect to creatinine or with respect to the amounts excreted 
within 24 h compared to healthy volunteers (Fig 2). The geometric 
mean was 51 nmol LTE4/mol creatinine (95% confidence interval: 
28-95 nmol LTE4/mol creatinine). The total amounts of urinary 
L TE4 were log normally distributed with a geometric mean of 
186 ng LTE4/24 h (95% confidence interval : 113-305 ng/LTE4/ 
24 h). 
DISCUSSION 
Measurement of index metabolites in urine has been demonstrated 
to be a very successful approach to evaluate the biologic functions of 
prostanoids and thromboxane [20J . In the present paper we mea-
sured excretion ofLTE4 into urine to assess whole-body synthesis of 
cysteinyl leukotrienes in psoriasis. We demonstrate a significant 
more than fourfold increase in the elimination of this index metabo-






































Figure 2. Leukotriene E. l.evels in urine of healthy volunteers (n = 11), 
open circles, and psoriasis (n = 8), open squares. Bars, geometric mean and 95% 
confidence interval. Note logarithmic scale of ordinate. 
lite of cysteinylleukotriene synthesis in psoriasis compared with the 
elimination of L TE4 by healthy volunteers. The excretion rate of 
LTE4 in our normal volunteers is in close proximity to the values 
reported by others [13,21]. Not only relative to creatinine but also 
the amounts ofLTE4 excreted within 24 h were enhanced in psoria-
sis compared to healthy volunteers. The identity of urinary LTE4 is 
unequivocally demonstrated by GC-MS (Fig 1). Furthermore, uri-
nary LTE4 was also quantitated by GC-MS. The differences ofL TE4 
values obtained by GC-MS and RIA were less than 10%. This 
clearly demonstrates that the combination of RP-HPLC followed 
by RIA is a suitable method for the quanti tat ion of L TE4 in urine. 
To date there are no data available concerning the day to day varia-
bility of L TE4 elimination into urine in humans. We therefore 
measured urinary L TE4 in 24-h urine samples collected from 
healthy volunteers on three consecutive days. A coefficient of varia-
tion of 8 ± 3% (mean ± SD) from day to day demonstrates that 
urinary L TE4 can be used to monitor disease activity and/or thera-
peutic intervention on leukotriene synthesis. It is obvious from 
these data that the difference in L TE4 excretion. between normal 
volunteers and patients with psoriasis cannot be due to sampling 
artefacts. 
However, it must be pointed out that urinary L TE4 is not a spe-
cific marker for psoriasis. In other diseases, such as asthma [22]. 
cardiac infarction [23] and multiple trauma [16,24], an enhanced 
urinary excretion of L TE4 has been demonstrated . From this it fol-
lows that L TE4 is not a specific index of a single disease but might 
instead provide a sensitive index of inflammation. This proposal is 
further supported by the demonstration of a correlation between the 
L TE4 concentration in sputum and the L TE4 excretion into urine in 
children with cystic fibrosis [25] . In the present work there was no 
strict correlation between urinary L TE4 and affected body surface. 
The relation to more inflammatory forms of psoriasis (pustular, 
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erythrodermic) remains to be established. Cysteinylleukotriene syn-
thesis does not seem to be enhanced per se in psoriasis as we found 
that urinary L TE4 from 3 patients declined to normal levels under 
conventional therapy. 
So far L TB4 was the only leukotriene demonstrated in lesional 
skin from psoriasis except for a report showing the presence of 
cysteinylleukotrienes in skin chamber fluid obtained from lesional 
but also lesion-free skin from patients with psoriasis [14] . The main 
cysteinylleukotrienes determined in skin chamber fluid were L TC4 
and LTD4. The presence of cysteinylleukotrienes in lesional and 
lesion-free skin led the authors to the conclusion that the presence 
of these mediators could be at least in part due to artificial generation 
during sampling procedure. 
All data concerning leukotrienes in psoriasis suggest a pathogenic 
role of these mediators in psoriasis. Although the present methodol-
ogy does not allow localizing the origin of this enhanced synthesis 
of cysteinylleukotrienes, our finding is in line with recent in vitro 
experiments [26] demonstrating an enhanced synthesis of cysteinyl 
leukotrienes by mast cells, Langerhans cells, and, most importantly, 
keratinocytes . These data are important as it has been shown that in 
the early phase of the disease infiltrating mast cells are the dominat-
ing cells, whereas in the later phase keratinocytes are predominat-
ing. 
Furthermore, keratinocytes are mainly involved in the enhanced 
proliferation typical of psoriasis. However, in vitro data from iso-
lated cells must be interpreted cautiously, as characteristically cells 
must be appropriately stimulated to synthesize leukotrienes. There-
fore, the extent of synthesis observed in in vitro experiments de-
pends upon the stimulation and reflects the ability and capacity of 
cells to synthesize leukotrienes . 
In conclusion, in the present paper we demonstrate enhanced 
cysteinyl leukotriene synthesis by a non-invasive, artifact-free 
method. Measurement of L TE4 in urine is a useful method to moni-
tor cysteinyl leukotriene synthesis in psoriasis. Furthermore, we 
suggest that measurement of L TE4 can also be used to monitor 
therapeutic interventions such as the effect of inhibitors of 5-lipox-
ygenase. Recently the local application of 5-1ipoxygenase inhibitors 
resulted in amelioration of disease activity in psoriasis [27,28] . 
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ANNOUNCEMENT 
The Third Dermatopathology Self Assessment Workshop will be held September 17 -19, 
1992 in Rome, Italy, with AB Ackerman (New York University, USA), E. Wilson-Jones 
(London University, UK), and R. Cerio (Royal London Hospital, UK). 
The workshop will provide an in-depth review of difficult topics in dermatopathology: 
malignant melanoma (AB Ackerman), vascular tumors (E. Wilson Jones), and immunohisto-
chemistry applied to dermatopathology (R. Cerio). 
The program will consist of a series of lectures and of a direct examination of slides. Micro-
scopes will be provided for the participants. The course fee is US $200 for participation in all the 
activities of the course or US $ 1 00 for those desmng to attend the lectures only. 
For further information please contact Guido Massi, MD, Department of Pathology, Catho-
lic University, Largo F. Vito, 1,00168 Rome, Italy; tel, (6) 3303481/30154270/5759733; fax, 
(6) 3051343. 
